Literature DB >> 2884171

Inhibition of meal stimulated gastric acid secretion by an octapeptide somatostatin analogue SMS 201-995.

J A Olsen, F B Loud, J Christiansen.   

Abstract

A dose response study of the effect of an octapeptide somatostatin analogue, SMS 201-995, on meal stimulated gastric acid secretion was carried out in 12 healthy volunteers. Infusion of SMS 201-995 in a dose of 50 pmol/kg/h almost completely abolished the acid response to the meal. Pl-gastrin was significantly decreased during infusion of 10 pmol/kg/h of SMS 201-995 and insulin was significantly inhibited during infusion of 50 pmol/kg/h. SMS 201-995 in a dose of 50 pmol/kg/h inhibited basal and submaximal pentagastrin stimulated acid secretion by 77% and 84% respectively (p less than 0.01). On a molar basis SMS 201-995 is substantially more potent than natural somatostatin in inhibiting gastric acid secretion.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2884171      PMCID： PMC1432826          DOI： 10.1136/gut.28.4.464

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  9 in total

1.  Somatostatin cell processes as pathways for paracrine secretion.

Authors:  L I Larsson; N Goltermann; L de Magistris; J F Rehfeld; T W Schwartz
Journal:  Science       Date:  1979-09-28       Impact factor: 47.728

2.  Somatostatin and ranitidine in the control of iatrogenic haemorrhage of the upper gastrointestinal tract.

Authors:  F Coraggio; P Scarpato; M Spina; S Lombardi
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-28

3.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

4.  Somatostatin and cimetidine in peptic-ulcer haemorrhage. A randomised controlled trial.

Authors:  L Kayasseh; K Gyr; U Keller; G A Stalder; M Wall
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

5.  Effect of growth hormone release-inhibiting hormone on gastric secretion, mucosal blood flow, and serum gastrin.

Authors:  S J Konturek; J Tasler; M Cieszkowski; D H Coy; A V Schally
Journal:  Gastroenterology       Date:  1976-05       Impact factor: 22.682

6.  Is somatostatin a humoral regulator of the endocrine pancreas and gastric acid secretion in man?

Authors:  F B Loud; J J Holst; E Egense; B Petersen; J Christiansen
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

7.  Intracellular receptor for somatostatin in gastric mucosal cells: decomposition and reconstitution of somatostatin-stimulated phosphoprotein phosphatases.

Authors:  F J Reyl; M J Lewin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

8.  Inhibition by somatostatin (growth-hormone release-inhibiting hormone, GH-RIH) of gastric acid and pepsin and G-cell release of gastrin.

Authors:  A A Barros D'sa; S R Bloom; J H Baron
Journal:  Gut       Date:  1978-04       Impact factor: 23.059

9.  Somatostatin in treatment of haematemesis and melaena.

Authors:  K W Somerville; D A Henry; J G Davies; K R Hine; C J Hawkey; M J Langman
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321
  9 in total
  3 in total

1.  Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome.

Authors:  K Ladefoged; K C Christensen; J Hegnhøj; S Jarnum
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

2.  Patterns of gastrin secretion in patients with nonfunctioning pituitary adenomas.

Authors:  L Persani; P Beck-Peccoz; M Quatrini; M Bassetti; B Travella; P Bianchi; G Faglia
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

3.  Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillus atrophy.

Authors:  R T Couper; A Berzen; G Berall; P M Sherman
Journal:  Gut       Date:  1989-07       Impact factor: 23.059
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.